NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT01744912 2022-05-11Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTG Therapeutics, Inc.Phase 1 Terminated10 enrolled
NCT04818372 2021-11-12Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaKeymed Biosciences Co.LtdPhase 1 Unknown87 enrolled
NCT02142049 2019-02-05Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaPharmacyclics LLC.Phase 1/2 Completed35 enrolled 18 charts